Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $657K, compared with -$23.28M a year earlier. Trailing-twelve-month EBITDA was -$17.44M.
Context
- EBITDA amounted to 83.1% of revenue in FY2025, down 509.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$39.48M (+4.6%) for the fiscal year ending Dec 2026, a slowdown from the +77.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $657K+104.9% QoQ
- Last fiscal yearDec 2025
- -$41.38M+77.5% YoY
- LTMMar 2026
- -$17.44M+88.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +102.8% | -441.8% | -544.6 pp |
| 1 year | +77.5% | +4.6% | -73.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (41.38M) USD
- Year-over-year change
- +77.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.38M) | +77.5% |
| FY2024 | 2024-12-31 | (184.29M) | -8.6% |
| FY2023 | 2023-12-31 | (169.76M) | -69.7% |
| FY2022 | 2022-12-31 | (100.03M) | -15.4% |
| FY2021 | 2021-12-31 | (86.66M) | — |
EBITDA vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 EBITDA of -$17.44M is the 4th highest of the 11 companies compared; the peer median is -$47.86M.
- Its year-over-year change of +88.7% is the 2nd highest of 11, against a peer median of -31.4%.
- EBITDA amounts to 25.0% of revenue for LXRX, versus a peer median of 38.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $131.28M | +170.9% | — | 43.8% | |
| LTM Mar 2026 | $27.55M | -66.6% | — | 7.6% | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
| LTM Sep 2026 | -$60.69M | -32.7% | — | — | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| LTM Jun 2026 | -$302.96M | -577.6% | — | 32.2% | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| Peer median (excluding LXRX) | -$47.86M | -31.4% | — | 38.0% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Cost of Revenue | 55.05M | 52.52M | 58.97M | 616K | 274K |
| Gross Profit | (54.75M) | (52.38M) | (57.77M) | 30.47M | 49.53M |
| Gross Margin | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| Research & Development | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Selling, General & Admin | 0 | 0 | 0 | 131.9M | 37.32M |
| Operating Expenses | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| EBITDA | (86.66M) | (100.03M) | (169.76M) | (184.29M) | (41.38M) |
| EBITDA Margin | -29081.9% | -71966.2% | -14099.3% | -592.9% | -83.1% |
| Operating Income | (87.09M) | (100.76M) | (171.75M) | (197.12M) | (48.91M) |
| Operating Margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Interest Income | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income / Expenses | (668K) | (1.18M) | (5.37M) | (3.29M) | (1.43M) |
| Income Before Tax | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Pre-Tax Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Net Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (Basic) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| EPS (Diluted) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| Weighted Avg Shares | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Weighted Avg Shares (Diluted) | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.